Cardiol Therapeutics Inc. Class A CRDL 深 滬
已收盤 01-30 16:00:00 美东时间
0.9507
-0.030
-3.04%
華盛通- 最 高0.9895
- 今 開0.96
- 成交量 27.40万股
- 最 低 0.9351
- 昨 收 0.9805
- 總市值 7960.15万
- 52周最高 1.59
- 市盈率 靜 --
- 換手率 0.33%
- 52周最低 0.7709
- 委 比 50.62%
- 總股本 8372.94万
- 歷史最高 4.96
- 量 比 1.06
- 振 幅 5.55%
- 歷史最低 0.45
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cardiol Therapeutics Surpasses 50% Participant Enrollment In MAVERIC Phase III Study Of CardiolRx
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
01-13 20:31
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute
2025-12-01 20:32
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last
2025-11-14 06:35
Cardiol Therapeutics Receives USPTO Notice Of Allowance For Patent On Cannabidiol Heart Therapies
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property
2025-11-13 20:49
Cardiol Therapeutics Secures $11M Financing, Advances Heart Disease Therapies
The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardi...
2025-10-18 05:06
Cardiol Therapeutics to Present at Canaccord Genuity Conference
Cardiol Therapeutics ( ($TSE:CRDL) ) has shared an announcement. Cardiol Therap...
2025-08-11 20:14
Cardiol Therapeutics Reports Compelling ARCHER Trial Results Supporting Advancement of CardiolRx And CRD-38 in Myocarditis And Heart Failure
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements
2025-08-06 19:29
Cardiol Locks Key Trial Data as It Advances New Treatment for Dangerous Heart Inflammation
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart
2025-07-22 19:33
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
2025-06-03 09:06
